The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
Have at least one diabetes-related autoantibody found at screening
Show signs of remaining beta-cell function
stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
Have any other type of diabetes including gestational
Have uncontrolled high blood pressure
Have had a heart attack, heart disease, stroke, or heart failure
Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy